Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Heidi C. Waters, Robert Stellhorn, Maelys Touya, Heather Fitzgerald, Sandipan Bhattacharjee & Leslie Citrome. (2023) The effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from US claims data. Journal of Medical Economics 26:1, pages 316-325.
Read now
Read now
Yanlin Wang, Xiaofeng Wang, Matt Harlin, Frank Larsen, Moeen Panni, Murat Yildirim, Jessica Madera, Liz Arias, Andy Forbes, Nihal Mustafa, Inez Ruiz-White & Arash Raoufinia. (2021) An alternative start regimen with aripiprazole once-monthly in patients with schizophrenia: population pharmacokinetic analysis of a single-day, two-injection start with gluteal and/or deltoid intramuscular injection. Current Medical Research and Opinion 37:11, pages 1961-1972.
Read now
Read now
Fabio Magliocco, Renato de Filippis, Matteo Aloi, Filippo Antonio Staltari, Raffaele Gaetano, Cristina Segura-Garcia & Pasquale De Fazio. (2020) Second-generation long-acting injections anti-psychotics improve executive functions in patients with schizophrenia: a 12-month real-world study. International Journal of Psychiatry in Clinical Practice 24:2, pages 201-207.
Read now
Read now
Jessica J Madera, Pedro Such, Cathy Zhao & Ross A Baker. (2019) Symptomatic stability with aripiprazole once-monthly: efficacy analyses from acute and long-term studies. Neuropsychiatric Disease and Treatment 15, pages 1593-1604.
Read now
Read now
Rosaria Di Lorenzo, Paola Ferri, Michela Cameli, Sergio Rovesti & Chiara Piemonte. (2019) Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting. Neuropsychiatric Disease and Treatment 15, pages 183-198.
Read now
Read now
Steven G Potkin & Adrian Preda. (2016) Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia. Expert Opinion on Pharmacotherapy 17:3, pages 395-407.
Read now
Read now
Leslie Citrome. (2016) Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil. Expert Review of Clinical Pharmacology 9:2, pages 169-186.
Read now
Read now
Rene S Kahn & Amalia Giannopoulou. (2015) The safety, efficacy and tolerability of Abilify Maintena for the treatment of schizophrenia. Expert Review of Neurotherapeutics 15:9, pages 969-981.
Read now
Read now
Arash Raoufinia, Ross A. Baker, Anna Eramo, Anna-Greta Nylander, Wally Landsberg, Dusan Kostic & Frank Larsen. (2015) Initiation of aripiprazole once-monthly in patients with schizophrenia. Current Medical Research and Opinion 31:3, pages 583-592.
Read now
Read now
Articles from other publishers (24)
Bernhard T. Baune. (2023) Aripiprazole 2-month ready-to-use 960 mg (Ari 2MRTU): review of its possible role in schizophrenia therapy. Current Medical Research and Opinion, pages 1-23.
Crossref
Crossref
Laurent Boyer, Bruno Falissard, Philippe Nuss, Cedric Collin, Stephanie Duret, Marc Rabbani, Isabelle De Chefdebien, Isabelle Tonelli, Pierre Michel Llorca & Guillaume Fond. (2023) Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders. Molecular Psychiatry.
Crossref
Crossref
Guillaume Fond, Bruno Falissard, Philippe Nuss, Cedric Collin, Stephanie Duret, Marc Rabbani, Isabelle De Chefdebien, Isabelle Tonelli, Pierre Michel Llorca & Laurent Boyer. (2023) How can we improve the care of patients with schizophrenia in the real-world? A population-based cohort study of 456,003 patients. Molecular Psychiatry.
Crossref
Crossref
Daniel Schöttle, Wolfgang Janetzky, Francois Therrien & Klaus Wiedemann. (2023) BPRS domains, items and subgroups analyses, and CGI-I ratings in pooled data from non-interventional studies of aripiprazole once-monthly in schizophrenia (REACT study). BMC Psychiatry 23:1.
Crossref
Crossref
Emily Menand & Rachel Moster. (2021) Racial Disparities in the Treatment of Schizophrenia Spectrum Disorders: How Far Have We Come?. Current Behavioral Neuroscience Reports 8:4, pages 179-186.
Crossref
Crossref
Chi-Un Pae, Changsu Han, Won-Myong Bahk, Soo-Jung Lee, Ashwin A. Patkar & Prakash S. Masand. (2021) Consideration of Long-Acting Injectable Antipsychotics for Polypharmacy Regimen in the Treatment of Schizophrenia: Put It on the Table or Not?. Clinical Psychopharmacology and Neuroscience 19:3, pages 434-448.
Crossref
Crossref
Taishiro Kishimoto, Katsuhiko Hagi, Shunya Kurokawa, John M Kane & Christoph U Correll. (2021) Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies. The Lancet Psychiatry 8:5, pages 387-404.
Crossref
Crossref
Nora Palomar-Ciria, Marta Migoya-Borja, Fanny Cegla-Schvartzman, Santiago Ovejero, Raquel Alvarez-Garcia, Hugo J. Bello & Enrique Baca-García. (2021) Early administration of aripiprazole long-acting injectable in acute inpatients with schizophrenia: a clinical report. International Clinical Psychopharmacology 36:2, pages 97-100.
Crossref
Crossref
Dalibor Karlović, Ante Silić, Danijel Crnković & Vjekoslav Peitl. (2020) Effects of aripiprazole long‐acting injectable antipsychotic on hospitalization in recent‐onset schizophrenia. Human Psychopharmacology: Clinical and Experimental 36:2.
Crossref
Crossref
Samskruthi Madireddy & Sahithi Madireddy. (2020) Regulation of Reactive Oxygen Species-Mediated Damage in the Pathogenesis of Schizophrenia. Brain Sciences 10:10, pages 742.
Crossref
Crossref
Chiara Rapinesi, Georgios D. Kotzalidis, Lorenzo Mazzarini, Roberto Brugnoli, Stefano Ferracuti, Sergio De Filippis, Ilaria Cuomo, Gloria Giordano, Antonio Del Casale, Gloria Angeletti, Gabriele Sani & Paolo Girardi. (2019) Long-Acting Injectable (LAI) Aripiprazole Formulations in the Treatment of Schizophrenia and Bipolar Disorder: a Systematic Review. Clinical Drug Investigation 39:8, pages 713-735.
Crossref
Crossref
Monica Aguilar & Benjamin Malcolm. (2019) Effect of long-acting aripiprazole monohydrate on inpatient encounters: A retrospective mirror image study. Mental Health Clinician 9:4, pages 258-262.
Crossref
Crossref
J. Potaufeu, B. Langrée, D. Drapier, G. Burgot & N. Marie. (2019) Étude coût-efficacité du pamoate d’olanzapine : analyse en miroir sur un an. L'Encéphale 45:3, pages 232-238.
Crossref
Crossref
Christoph Potempa & Reinhard Rychlik. (2018) Hospitalization rates and resource utilization of schizophrenic patients switched from oral antipsychotics to aripiprazole-depot in Germany. Health Economics Review 8:1.
Crossref
Crossref
Muneto Izuhara, Hiroyuki Matsuda, Ami Saito, Maiko Hayashida, Syoko Miura, Arata Oh-Nishi, Ilhamuddin Abdul Azis, Rostia Arianna Abdullah, Keiko Tsuchie, Tomoko Araki, Arauchi Ryousuke, Misako Kanayama, Sadayuki Hashioka, Rei Wake, Tsuyoshi Miyaoka & Jun Horiguchi. (2018) Cognitive Behavioral Therapy for Insomnia as Adjunctive Therapy to Antipsychotics in Schizophrenia: A Case Report. Frontiers in Psychiatry 9.
Crossref
Crossref
Hidenobu Suzuki, Hiroyuki Hibino, Yuichi Inoue & Atsuhiko Takaya. (2018) Changes in length of hospital stay and number of hospitalization before and after the administration of three second-generation antipsychotics long-acting injections in patients with schizophrenia: Mirror-image study. Asian Journal of Psychiatry 34, pages 43.
Crossref
Crossref
Takakuni Matsuda. (2018) ABILIFY MAINTENA<sup>®</sup>（aripiprazole） for extended-release antipsychotic injectable suspension for schizophrenia持続性抗精神病薬 エビリファイ<sup>®</sup>持続性水懸筋注用. Drug Delivery System 33:2, pages 151-155.
Crossref
Crossref
Joseph R. Calabrese, Raymond Sanchez, Na Jin, Joan Amatniek, Kevin Cox, Brian Johnson, Pamela Perry, Peter Hertel, Pedro Such, Robert D. McQuade, Margaretta Nyilas & William H. Carson. (2018) Symptoms and functioning with aripiprazole once-monthly injection as maintenance treatment for bipolar I disorder. Journal of Affective Disorders 227, pages 649-656.
Crossref
Crossref
Zahinoor IsmailTimothy Peters-StricklandMaia MiguelezRoss A. BakerPeter HertelAnna EramoNa JinPamela PerryRaymond SanchezRobert D. McQuadeJohn M. Kane. (2017) Aripiprazole Once-Monthly in the Treatment of Acute Psychotic Episodes in Schizophrenia. Journal of Clinical Psychopharmacology 37:3, pages 347-350.
Crossref
Crossref
Enrico Biagi, Enrico Capuzzi, Fabrizia Colmegna, Alessandra Mascarini, Giulia Brambilla, Alessandra Ornaghi, Jacopo Santambrogio & Massimo Clerici. (2017) Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly. Advances in Therapy 34:5, pages 1036-1048.
Crossref
Crossref
Arash Raoufinia, Timothy Peters-Strickland, Anna-Greta Nylander, Ross A. Baker, Anna Eramo, Na Jin, Patricia Bricmont, Jennifer Repella, Robert D. McQuade, Peter Hertel & Frank Larsen. (2017) Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration. International Journal of Neuropsychopharmacology 20:4, pages 295-304.
Crossref
Crossref
Timothy Peters-Strickland, Cathy Zhao, Pamela P. Perry, Anna Eramo, Phyllis M. Salzman, Robert D. McQuade, Brian R. Johnson & Raymond Sanchez. (2016) Effects of aripiprazole once-monthly on symptoms of schizophrenia in patients switched from oral antipsychotics. CNS Spectrums 21:6, pages 460-465.
Crossref
Crossref
E. Fakra, J.-M. Azorin, R. Belzeaux, M. Adida, O. Blin & A. Kaladjian. (2016) Comment ?valuer l?efficacit? d?un antipsychotique d?action prolong?e au moyen d?un essai clinique ?. L'Enc?phale 42:6, pages S43-S46.
Crossref
Crossref
Sourabh Moti Singh, Peter M. Haddad, Nusrat Husain, Eamonn Heaney, Barbara Tomenson & Imran B. Chaudhry. (2016)
Cross-sectional comparison of first-generation antipsychotic long-acting injections
vs
risperidone long-acting injection: patient-rated attitudes, satisfaction and tolerability
. Therapeutic Advances in Psychopharmacology 6:3, pages 162-171.
Crossref
Crossref